Avisa Diagnostics Inc. (FOGCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avisa Diagnostics Inc. (FOGCF) trades at $0.00 with AI Score 45/100 (Grade C). Avisa Diagnostics Inc. is a clinical-stage medical device company focused on developing the Avisa BreathTest, a platform for rapid detection of bacterial pathogens. Market cap: $97,176, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for FOGCF: FOGCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FOGCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FOGCF: the 1 perspectives are evenly split.
How is this calculated? →Avisa Diagnostics Inc. (FOGCF) Healthcare & Pipeline Overview
Avisa Diagnostics Inc. is a clinical-stage medical device company specializing in the development of the Avisa BreathTest, a novel drug/device biomarker platform for the ultra-rapid detection of virulent bacterial pathogens. The company targets respiratory infections and aims to improve diagnostics and monitoring of bacterial load, positioning itself within the pharmaceuticals sector.
What Is the Investment Thesis for FOGCF?
Avisa Diagnostics Inc. presents a notable research candidate due to its innovative Avisa BreathTest platform, which addresses a critical need for rapid and accurate bacterial pathogen detection. The company's focus on respiratory infections, including post-COVID-19 bronchiectasis and ventilator-associated pneumonia, positions it to capitalize on emerging market demands. Key value drivers include successful completion of pivotal clinical trials, regulatory approvals, and commercial partnerships. The company's gross margin of 46.5% indicates potential for strong profitability upon commercialization. However, the negative P/E ratio of -0.23 and profit margin of -263.8% highlight the risks associated with a clinical-stage company that is not yet generating revenue. Upcoming catalysts include the progression of clinical trials and potential FDA approvals. Investors should monitor trial outcomes and regulatory milestones closely.
Based on FMP financials and quantitative analysis
FOGCF Key Highlights
- Gross Margin of 46.5% demonstrates the potential for strong profitability upon commercialization of the Avisa BreathTest platform.
- Focus on respiratory infections addresses a significant market need for rapid and accurate bacterial pathogen detection.
- Clinical trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia provide proof-of-concept for the Avisa BreathTest technology.
- Pivotal trials in post-COVID-19 bronchiectasis and ventilator-associated pneumonia target emerging market opportunities.
- Beta of -0.95 suggests lower volatility compared to the overall market, potentially offering some downside protection.
Who Are FOGCF's Competitors?
FOGCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.64 | -1.26% | $535.91M | 55 |
| BPMUF Basilea Pharmaceutica AG | $60.27 | +0.00% | $746.00M | 58 |
| CALZF PolyNovo Limited | $0.62 | +0.00% | $428.32M | 49 |
| ELTP Elite Pharmaceuticals, Inc. | $0.36 | +6.41% | $393.14M | 53 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FOGCF's Key Strengths?
- Innovative Avisa BreathTest platform for rapid bacterial detection.
- Focus on unmet needs in respiratory infection diagnostics.
- Clinical trials demonstrating proof-of-concept.
- Strong intellectual property protection.
What Are FOGCF's Weaknesses?
- Clinical-stage company with no current revenue.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources.
- OTC market listing.
What Could Drive FOGCF Stock Higher?
- Completion of pivotal clinical trials for Post-COVID-19 bronchiectasis.
- FDA submission for the Avisa BreathTest platform.
- Announcement of strategic partnerships with pharmaceutical companies.
- Enrollment of patients in clinical trials for ventilator-associated pneumonia.
- Publication of clinical trial results in peer-reviewed journals.
What Are the Key Risks for FOGCF?
- Failure to obtain regulatory approvals for the Avisa BreathTest.
- Unsuccessful clinical trial outcomes.
- Competition from established diagnostic companies.
- Limited financial resources to support research and development.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for FOGCF?
- Expansion into Post-COVID-19 Bronchiectasis Diagnostics: The increasing prevalence of post-COVID-19 bronchiectasis presents a significant growth opportunity for Avisa Diagnostics. The company's pivotal trials in this area could lead to the development of a rapid and accurate diagnostic test, addressing an unmet need in the management of this condition. The market for post-COVID-19 diagnostics is expected to grow substantially in the coming years, offering a substantial revenue stream for Avisa.
- Ventilator-Associated Pneumonia (VAP) Diagnostics: Avisa's focus on ventilator-associated pneumonia (VAP) diagnostics represents another key growth opportunity. VAP is a common and serious complication in mechanically ventilated patients, and rapid diagnosis is crucial for effective treatment. The Avisa BreathTest could provide a faster and more accurate alternative to traditional diagnostic methods, potentially improving patient outcomes and reducing healthcare costs. The VAP diagnostics market is estimated to be worth hundreds of millions of dollars annually.
- Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop companion diagnostics for antibiotic therapies represents a strategic growth opportunity for Avisa Diagnostics. By identifying patients who are most likely to benefit from specific antibiotics, the Avisa BreathTest could improve treatment efficacy and reduce antibiotic resistance. Such partnerships could generate significant revenue through licensing agreements and royalties.
- Expansion into New Geographic Markets: Expanding into new geographic markets, particularly in developing countries where respiratory infections are highly prevalent, presents a significant growth opportunity for Avisa Diagnostics. The company could partner with local distributors and healthcare providers to introduce the Avisa BreathTest platform to these markets. This expansion could significantly increase the company's revenue and market share.
- Development of New BreathTest Applications: The Avisa BreathTest platform has the potential to be adapted for the detection of other types of pathogens and diseases. Avisa Diagnostics could invest in research and development to expand the applications of its platform, creating new revenue streams and diversifying its product portfolio. This could include developing breath tests for fungal infections, viral infections, and even certain types of cancer.
What Opportunities Does FOGCF Have?
- Expansion into new respiratory infection diagnostics.
- Partnerships with pharmaceutical companies.
- Geographic expansion into developing markets.
- Development of new BreathTest applications.
What Threats Does FOGCF Face?
- Competition from established diagnostic companies.
- Failure to obtain regulatory approvals.
- Unsuccessful clinical trial outcomes.
- Changes in healthcare regulations and reimbursement policies.
What Are FOGCF's Competitive Advantages?
- Proprietary Avisa BreathTest technology platform.
- Patents protecting the BreathTest technology and its applications.
- Clinical data demonstrating the efficacy of the BreathTest.
- Established relationships with key opinion leaders in respiratory medicine.
- First-mover advantage in the market for rapid bacterial pathogen detection.
What Does FOGCF Do?
Avisa Diagnostics Inc., based in Santa Fe, New Mexico, is a clinical-stage medical device company focused on revolutionizing the detection and monitoring of bacterial pathogens. The company is developing the Avisa BreathTest, a proprietary drug/device biomarker technology platform that enables the ultra-rapid identification and quantification of virulent bacteria. The core innovation involves patients inhaling or ingesting specific drug substrates, followed by the analysis of their breath to detect bacterial presence and load. Avisa Diagnostics is currently conducting clinical trials to validate its technology across a range of respiratory infections. These include cystic fibrosis, tuberculosis, and community-acquired pneumonia, where rapid and accurate diagnostics are critical for effective treatment. The company is also focusing on pivotal trials in emerging areas such as post-COVID-19 bronchiectasis and ventilator-associated pneumonia, addressing unmet needs in these patient populations. Avisa Diagnostics aims to provide clinical proof-of-concept through these trials, paving the way for regulatory approvals and commercialization of the Avisa BreathTest platform. The company's strategic focus on respiratory infections positions it to address a significant market opportunity in infectious disease diagnostics.
What Products and Services Does FOGCF Offer?
- Develops the Avisa BreathTest, a drug/device biomarker technology platform.
- Enables ultra-rapid detection of virulent bacterial pathogens.
- Detects and monitors bacterial load after drug substrate inhalation or ingestion.
- Offers clinical proof-of-concept through trials in cystic fibrosis.
- Conducts trials in tuberculosis and community-acquired pneumonia.
- Focuses on pivotal trials in Post-COVID-19 bronchiectasis.
- Targets ventilator-associated pneumonia with diagnostic solutions.
How Does FOGCF Make Money?
- Develops and patents the Avisa BreathTest technology.
- Conducts clinical trials to validate the efficacy of the BreathTest.
- Seeks regulatory approvals for the BreathTest platform.
- Commercializes the BreathTest through direct sales or partnerships.
- Generates revenue through sales of BreathTest kits and related services.
What Industry Does FOGCF Operate In?
The medical diagnostics industry is experiencing rapid growth, driven by increasing demand for faster and more accurate diagnostic tools. The global molecular diagnostics market is projected to reach billions of dollars by 2028. Avisa Diagnostics operates in this dynamic landscape, focusing on the detection of bacterial pathogens in respiratory infections. Competitors include companies like BJTRF (BioJector A/S), BPMUF (BioPorto A/S), CALZF (Calzyme Laboratories Inc.), ELTP (Elite Pharmaceuticals Inc.), and MNFSF (MannKind Corporation), each with varying approaches to diagnostics and therapeutics. Avisa's BreathTest platform offers a unique approach to rapid detection, potentially providing a competitive advantage in the market.
Who Are FOGCF's Key Customers?
- Hospitals and clinics treating patients with respiratory infections.
- Diagnostic laboratories performing bacterial pathogen testing.
- Pharmaceutical companies developing antibiotic therapies.
- Research institutions conducting studies on respiratory diseases.
- Patients requiring rapid and accurate diagnosis of bacterial infections.
ROE 409%Key Financial Metrics
Return on equity for Avisa Diagnostics Inc. stands at 408.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.23 means current liabilities exceed short-term assets, a liquidity point worth watching.
How Avisa Diagnostics Inc. Is Valued
Avisa Diagnostics Inc. carries a market capitalization of 97K, placing it in the micro-cap category. Relative to its peer group, FOGCF's quantitative score of 45/100 is below the peer average of 57/100.
FOGCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Avisa's growth trajectory, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of Avisa's diagnostic solutions and their relevance in current healthcare trends.
- Recent partnerships or collaborations have been perceived favorably, showcasing Avisa's ability to leverage its technology in the market.
- Increased media coverage has sparked interest, with analysts praising Avisa's unique approach to diagnostics as a potential game-changer.
Bear Case
- Concerns have been raised about the competitive landscape, with many questioning how Avisa will differentiate itself from established players in diagnostics.
- Recent social sentiment has shown skepticism regarding the scalability of Avisa's technology, with some community members expressing doubts about market adoption.
- Market perception has been impacted by regulatory uncertainties, leading to hesitance among potential investors and stakeholders.
- Some bearish analysts have pointed out that despite recent positive developments, Avisa still faces significant challenges in achieving profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
FOGCF Latest News
No recent news available for FOGCF.
FOGCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FOGCF.
Price Targets
Wall Street price target analysis for FOGCF.
FOGCF MoonshotScore
What does this score mean?
The MoonshotScore rates FOGCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David S. Joseph
CEO
David S. Joseph serves as the CEO of Avisa Diagnostics Inc. His background includes extensive experience in the medical device and diagnostics industries. He has held leadership positions in various companies, focusing on strategic planning, product development, and commercialization. Joseph's expertise spans across multiple therapeutic areas, including infectious diseases and respiratory medicine. He holds advanced degrees in business and science, providing a strong foundation for leading a clinical-stage company.
Track Record: Under David S. Joseph's leadership, Avisa Diagnostics has advanced its Avisa BreathTest platform through key clinical trials, demonstrating its potential for rapid bacterial pathogen detection. He has successfully secured funding to support the company's research and development efforts. Joseph has also forged strategic partnerships with leading research institutions and healthcare providers to accelerate the development and commercialization of the BreathTest technology.
FOGCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avisa Diagnostics Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and may be subject to greater risks. Investing in OTC Other stocks requires careful due diligence and a thorough understanding of the company's business and financial condition. Companies in this tier may not be required to adhere to strict reporting standards, increasing information asymmetry.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure may hinder informed investment decisions.
- Lower trading volume can lead to price volatility and illiquidity.
- Increased risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or suspension of trading.
- Higher bid-ask spreads can increase transaction costs.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Monitor the company's news releases and SEC filings.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Focus on clinical trials and scientific validation.
- Partnerships with reputable research institutions.
- Experienced management team with relevant industry expertise.
- Development of a novel technology platform.
- Presence of intellectual property protection.
Avisa Diagnostics Inc. Healthcare Stock: Key Questions Answered
What does Avisa Diagnostics Inc. do?
Avisa Diagnostics Inc. is a clinical-stage medical device company focused on developing and commercializing the Avisa BreathTest, a novel drug/device biomarker platform for the rapid detection of bacterial pathogens. The company's technology enables the ultra-rapid identification and quantification of virulent bacteria in respiratory infections. Avisa Diagnostics is currently conducting clinical trials to validate its technology across a range of respiratory infections, including cystic fibrosis, tuberculosis, post-COVID-19 bronchiectasis, and ventilator-associated pneumonia. The company aims to provide faster and more accurate diagnostic solutions for infectious diseases.
What do analysts say about FOGCF stock?
As a company trading on the OTC market with limited analyst coverage, there is currently no readily available analyst consensus on FOGCF stock. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio and revenue growth, should be considered in the context of the company's stage of development and the risks associated with investing in clinical-stage companies. The company's growth potential is dependent on the successful completion of clinical trials and regulatory approvals.
What are the main risks for FOGCF?
The main risks for Avisa Diagnostics Inc. include the inherent uncertainties associated with clinical-stage companies, such as the risk of unsuccessful clinical trial outcomes and the failure to obtain regulatory approvals for the Avisa BreathTest platform. The company also faces competition from established diagnostic companies and the risk of changes in healthcare regulations and reimbursement policies. Limited financial resources and dependence on key personnel and strategic partnerships also pose significant risks. Additionally, the company's OTC market listing increases the risk of illiquidity and price volatility.
What are the key factors to evaluate for FOGCF?
Avisa Diagnostics Inc. (FOGCF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does FOGCF data refresh on this page?
FOGCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FOGCF's recent stock price performance?
Avisa Diagnostics Inc. (FOGCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Avisa BreathTest platform for rapid bacterial detection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FOGCF overvalued or undervalued right now?
Valuing Avisa Diagnostics Inc. (FOGCF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FOGCF?
Before investing in Avisa Diagnostics Inc. (FOGCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be limited and less reliable than listed exchange data.
- AI analysis pending may provide further insights in the future.